IDEXX Laboratories, Inc. (IDXX) 47th Annual Raymond James Institutional Investor Conference March 2, 2026 9:15 AM ESTCompany ParticipantsJay Mazelsky ...

BofA Securities Animal Health Summit February 26, 2026 9:50 AM ESTCompany ParticipantsAndrew Emerson - Executive VP, ...

Celebrating the company’s 26th Anniversary at Natural Products Expo West 2026, Essential Formulas continues its family-owned mission of providing superior supplements guided by science and tradition.

OverviewThe Global Weight Loss Drugs Market is valued at USD 2.88 Billion in 2024 and is projected to reach a value of USD ...

Slowing population growth could soon weigh on the U.S. economy, trimming an estimated $104 billion from the country's gross domestic product compared with what it would have been if population growth ...

Switzerland will vote on capping its population at 10 million by 2050, a right-wing Swiss People's Party plan that pits immigration limits against labour needs. Switzerland will hold a referendum this ...

In the Phase 3 EV-304 trial, statistically significant improvements in overall survival and pathological complete response were also observed, with over half of patients having no detectable disease ...

Switzerland is to hold a landmark vote on a right-wing party’s proposal to restrict the nation’s population to 10 million, amid divisions over immigration. The proposal, put forward by the country’s ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced KEYTRUDA® (pembrolizumab) plus ...

The United States Digestive Enzyme Supplements Market is projected to grow from US$ 0.45 billion in 2025 to US$ 0.68 billion by 2033, at a CAGR of 5.37%. This growth is driven by rising awareness of ...

A proposal by anti-immigration Swiss People's Party has gained enough signatures to head to a referendum this June. But lawmakers and business groups argue the move could cause economic chaos.

Late-breaking KEYNOTE-B15 data show KEYTRUDA ® (pembrolizumab) plus Padcev ® (enfortumab vedotin-ejfv) significantly improved event-free survival, overall survival and pathologic complete response ...